Cx 611

Drug Profile

Cx 611

Alternative Names: Adipose-derived allogenic stem cell therapy - TiGenix NV; Cx611; eASC - TiGenix

Latest Information Update: 03 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellerix
  • Developer TiGenix
  • Class Antirheumatics; Antiseptics; Stem cell therapies
  • Mechanism of Action Cell replacements; Cytokine modulators; Immunomodulators; Inflammation mediator inhibitors; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Rheumatoid arthritis; Sepsis

Most Recent Events

  • 31 Jul 2018 TiGenix has been acquired by Takeda
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Sepsis(In volunteers) in Netherlands (IV, Suspension)
  • 31 Jan 2017 TiGenix initiates enrolment in the phase I/II SEPCELL trial for Sepsis in Spain and Belgium (EudraCT2015-002994-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top